Advertisement

Topics

Latest "Distributed Bio Inc." News Stories

07:11 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Distributed Bio Inc." found in our extensive news archives from over 250 global news sources.

More Information about Distributed Bio Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Distributed Bio Inc. for you to read. Along with our medical data and news we also list Distributed Bio Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Distributed Bio Inc. Companies for you to search.

Showing "Distributed" News Articles 1–25 of 744

Friday 15th February 2019

Aradigm Announces Plans for Reorganization Under Chapter 11 of the U.S. Bankruptcy Code

Aradigm Corporation (OTCQB: ARDM) (“Aradigm” or the “Company”) has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the Alameda County Court District to facilitate the sale of its assets. On February 11, 2019, Aradigm determined that without confirmation of funding from their primary investor and partner, the Company would not...


AHF Lauds Congress and the President for Boosting Global AIDS Funding

Funding bill will appropriate $5.72 billion for PEPFAR and $1.35 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria AIDS Healthcare Foundation (AHF) praised today the U.S. Congress and President Trump for adopting bipartisan appropriations l

Acarix adapts pathway for German reimbursement - Submission of new dossier by the end of February 2019

Press release Malmö, February 15, 2019 Acarix adapts pathway for German reimbursement - Submission of new dossier by the end of February 2019 Acarix AB (publ) (ACARIX: FN Stockholm) today announced it will file for German reimbursement directly with the Federal Joint Committee (G-BA) for its CADScorSystem®. Previously, Acarix was aiming for full reimbursement in Germany by the end of 2...


Thursday 14th February 2019

IEEE Completes Standards Family Intended to Provide Safe and Secure Medical Device Interoperability

IEEE 11073-20701TM-2018 defines an architecture that binds the participant and communication model to the Web services data transport model defined in previous IEEE 11073™ standards. IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE-SA), today ...

Martin Åmark, CEO for Xbrane Biopharma AB, becomes Head of IR for the Company

Press release2019-02-14 Martin Åmark, CEO of Xbrane Biopharma AB ("Xbrane"), will as of today also be the Head of IR for Xbrane. The reason for this is that Xbrane's current Head of IR and CFO, Susanna Helgesen, will be on parental leave on a part-time basis for a period. During the parental leave, Susanna Helgesen will remain as CFO. The finance team has also bee...

Active Biotech Year-end report January - December 2018

          Fourth quarter in brief Active Biotech communicated updated information about its financial position New data from the LEGATO-HD study presented at the 2018 HSG conference Other significant events during the January-December period Patent regarding tasquinimod for the treatment of multiple myeloma (MM) granted in the US

Ossur Hf : Annual General Meeting 7 March 2019

Announcement no. 10/201914 February 2019 Össur hf. - Annual General Meeting 7 March 2019 Össur hf.'s Annual General Meeting will be held on Thursday 7 March 2019 at 9:00 am (GMT) at the Company's offices at Grjótháls 5, Reykjavik, Iceland. Enclosed the convocation and proposed agenda for the Annual General Meeting, as well as proposed resolutions and remarks on each item on...

Wednesday 13th February 2019

Vistin Pharma ASA : Invitation to Q4 conference call

Oslo, Norway, 13 February 2019 Vistin Pharma ASA will release its fourth quarter 2018 results on Tuesday 19 February 2019. Reference is also made to the business updates from the company on 4 January and 8 January. Vistin Pharma will host a conference call for all shareholders and interested parties on 19 February at 10:00 CET. There will be a Q&A session following the mana...

Trading in Novo Nordisk shares by board members, executives and associated persons on 12 February 2019

Bagsværd, Denmark, 13 February 2019 - This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have given Novo Nordisk power of attorney...

Banner Health Chooses CommScope for Systemwide In-Building Mobile Wireless

Banner Health, a Phoenix, Arizona based healthcare provider with hospitals and clinics in six states, has selected the CommScope Era C-RAN antenna system to deliver strong, consistent mobile coverage in its facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190213005054/en/

Tuesday 12th February 2019

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2019

Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2019 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers) Charenton-le-Pont, France (February 12, 2019 - 6:00 pm) As of January 31, 2019, shares and voting rights outstanding of EssilorLuxottica, t...

ClearDATA Previews Machine Learning Solution at HIMSS19 to Track Patient Data as It Moves Through the Cloud

Attendees get a first look at the upcoming Healthcare Aware Distributed Tracing™ solution by ClearDATA that enhances the visibility of Protected Health Information (PHI) to build a secure data inventory that keeps organizations compliant. ClearDATA®, a leading healthcare cloud, security and

Sanofi appoints Ameet Nathwani Chief Digital Officer

  Press Release  Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)                                                                                                                                                              ...

Monday 11th February 2019

Kiadis Pharma to participate in a panel at Innovation for Health 2019

   Kiadis Pharma to participate in a panel at Innovation for Health 2019 Amsterdam, The Netherlands, February 11, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it is scheduled to participate in a panel at the Innovation for Health 2019 Confer...

MiraMed Provides Coats to Those in Need with Its Circle of Warmth Campaign

MiraMed Global Services, Inc. (MiraMed), a leader in healthcare revenue cycle management (RCM) services and business process outsourcing (BPO) solutions, is pleased to announce that its recent Circle of Warmth campaign raised $75,000+ dollars for those in

Orion and Propeller Health partner to bring new digital medicines to people with asthma and COPD

Orion Corporation                                  Press release  11 February 2019 at 4.00 p.m. EET Orion and Propeller Health partner to bring new digital medicines to people with asthma and COPD Orion Corporation and Propeller Health, a leading digital therapeutics company, today announced a partnership to connect the Easyhaler® line of inhaler...

Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study

PRESS RELEASE Lund Sweden, February 11 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that their partner NeoTX enters a clinical collaboration with AstraZeneca Group Plc (NYSE: AZN) global biologics research and development arm, MedImmune, to support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca's IMFINZI®. IMFINZI® (durvalumab) is a human...

Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first adult subjects in study C-001, a phase 1 pharmacodynamics clinical trial of OP0201, the company’s lead product candidate being developed for ...

Immunicum AB (publ) Announces First Patient Treated in Phase Ib/II ILIAD Combination Trial

Press Release 11 February 2019 Immunicum AB (publ) Announces First Patient Treated in Phase Ib/II ILIAD Combination Trial Immunicum AB (publ; IMMU.ST) announced today that the first patient has been treated in the Phase Ib/II ILIAD clinical trial. The trial will evaluate the safety and efficacy of Immunicum's lead product in development, ilixadencel, in combination with checkpoi...

Friday 8th February 2019

United Breast Cancer Foundation at the 61st Grammy® Awards

UBCF’s Print PSA #FluantYourFight featured in the Grammy® Awards Commemorative Program HUNTINGTON STATION, N.Y. (PRWEB) February 08, 2019 United Breast Cancer Foundation (UBCF) is pleased to announce the publication of their new print Public Service Announcement (PSA), #FlauntYourFight, in the 61st Annual Grammy® Awards Program. The Grammy® Awards, “Music’s Biggest Night,” ...

FDA Launches New Track-and-Trace Pilot Program

The program aims to reduce the amount of illegal or suspect prescription drugs distributed throughout the United States.

Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2019

DUBLIN - February 8, 2019 - Medtronic plc (NYSE:MDT) announced today that it will report financial results for the third quarter of fiscal year 2019 on Tuesday, February 19 , 2019. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for t...

Ambu A/S: Articles of Association February 2019

Complete Articles of Association February 2019 Complete AoA February 2019This announcement is distributed by West Corporation on behalf of West Corporation clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: Ambu A/S via Globenewswire

Invitation: Terveystalo Plc full-year 2018 result - Webcast and conference call on 14 February 2019

Terveystalo Plc will publish its full-year 2018 result on 14 February at 9:00 EET. (Finnish time). The report and related materials will be available on https://www.terveystalo.com/en/investors/Financial-information/ after publishing.  The company will hold a result briefing and live webcast in English on February 14, 2019, starting at 11:00 a.m. EET, at Terveystalo Piazza, Jaakonkatu ...

Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milestone payment to Basilea from Pfizer

Basilea Pharmaceutica AG / Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milestone payment to Basilea from Pfizer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Basel, Switzerland, February 08, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the European sales of ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks